Becton Dickinson and Company (BDX)vsWarby Parker Inc (WRBY)
BDX
Becton Dickinson and Company
$158.27
+1.51%
HEALTHCARE · Cap: $56.49B
WRBY
Warby Parker Inc
$23.38
+1.39%
HEALTHCARE · Cap: $2.86B
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 2414% more annual revenue ($21.92B vs $871.90M). WRBY leads profitability with a 19.0% profit margin vs 8.0%. BDX trades at a lower P/E of 25.5x. BDX earns a higher WallStSmart Score of 61/100 (C+).
BDX
Buy61
out of 100
Grade: C+
WRBY
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+36.9%
Fair Value
$286.42
Current Price
$158.27
$128.15 discount
Margin of Safety
-31314.3%
Fair Value
$0.07
Current Price
$23.38
$23.31 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Earnings expanding 28.6% YoY
Every $100 of equity generates 46 in profit
Areas to Watch
Moderate valuation
1.6% revenue growth
ROE of 7.0% — below average capital efficiency
Distress zone — elevated risk
0.0% earnings growth
Weak financial health signals
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : BDX
The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bull Case : WRBY
The strongest argument for WRBY centers on Return on Equity. Profitability is solid with margins at 19.0% and operating margin at -4.5%. Revenue growth of 11.2% demonstrates continued momentum.
Bear Case : BDX
The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : WRBY
The primary concerns for WRBY are EPS Growth, Piotroski F-Score, P/E Ratio. A P/E of 2338.0x leaves little room for execution misses.
Key Dynamics to Monitor
BDX profiles as a value stock while WRBY is a mature play — different risk/reward profiles.
WRBY carries more volatility with a beta of 2.06 — expect wider price swings.
WRBY is growing revenue faster at 11.2% — sustainability is the question.
BDX generates stronger free cash flow (549M), providing more financial flexibility.
Bottom Line
BDX scores higher overall (61/100 vs 34/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Warby Parker Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Warby Parker Inc. is an innovative leader in the direct-to-consumer eyewear market, redefining the optical landscape since its founding in 2010. By seamlessly blending a robust online platform with a growing number of physical retail outlets, the company enhances customer engagement while maintaining a focus on stylish, affordable prescription eyewear and sunglasses. Warby Parker's commitment to social impact is exemplified by its "Buy a Pair, Give a Pair" initiative, which fosters community support by providing eyewear to those in need. With a unique brand identity and forward-thinking marketing strategies, Warby Parker is well-positioned for continued expansion and enduring success in the competitive eyewear industry.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?